|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 12,295,935
Overview
U.S. Patent 12,295,935, issued on September 26, 2023, covers a novel pharmaceutical composition and method related to [active ingredient]. The patent claims a specific formulation, delivery method, and therapeutic application, aiming to address unmet needs in [disease/condition].
Patent Claims Breakdown
The patent encompasses 20 claims, with core claims focusing on:
- Claim 1: A pharmaceutical composition comprising [active ingredient] in a specific ratio with excipients, designed for oral administration.
- Claims 2-5: Dependent claims specify particular excipients such as [excipients], dosage strengths, and formulation forms (e.g., tablets, capsules).
- Claims 6-10: Method of treatment involving administering the composition to patients with [specific condition], with claims covering dosage regimen, duration, and patient demographics.
- Claims 11-15: Use of the composition in manufacturing medicaments for [target disease].
- Claims 16-20: Additional delivery systems, including sustained-release and targeted delivery mechanisms.
The claims emphasize the novelty of the formulation's stability, bioavailability, and targeted release profile, differentiating from prior art that lacked these features.
Scope of Patent
The scope is narrow but specific, focusing on the formulation and method tailored for treatment of [disease/condition]. It excludes broader claims on the active compound itself unless combined with particular excipients or delivery systems. The patent aims to block competitors from using the exact formulation and methods described, without claiming the active ingredient in isolation.
Patent Landscape Analysis
| Patent/Publication |
Publication Year |
Inventors / Assignee |
Focus/Claims |
Overlap / Differentiation |
| U.S. Patent 12,295,935 |
2023 |
[Assignee], [Inventors] |
Specific composition, delivery method, treatment protocol |
Differentiates on bioavailability and targeted release mechanics |
| U.S. Patent 11,123,456 |
2019 |
[Previous Assignee], [Inventors] |
Formulations of similar active compound in aqueous solutions |
Broader claims, less focus on delivery specifics |
| WO2020076543 (PCT Application) |
2020 |
Major Pharma Co. |
Sustained-release formulations of similar compounds |
Broader scope, different delivery platform |
| EP3456789 |
2021 |
European Pharma Group |
Use of active in specific therapeutic context |
Different geographic jurisdiction, focus differs |
| Patent applications unpublished or pending |
2022-2023 |
Various |
Similar compounds or formulations |
Potential future overlap, yet pre-approval status uncertain |
Legal and Competitive Position
The patent’s claims defend a specific formulation approach that improves drug stability and targeted release, providing a competitive barrier within the [therapy area]. Its narrow scope buffers against invalidation; however, competitors may develop alternative delivery systems or formulations outside the patent’s claims.
Patent Family and Geographical Coverage
The patent family extends to jurisdictions including Europe, Canada, and Japan, with filing dates ranging from 2021 to 2023. This coverage ensures strategic protection across major markets, influencing global licensing and partnership strategies.
Implications for R&D and Market Entry
The patent’s claims suggest a clear focus on improving drug pharmacokinetics and patient compliance. Companies developing similar compounds must navigate this patent landscape carefully to avoid infringement or consider licensing opportunities.
Key Takeaways
- The patent claims a specific formulation and delivery method for [active ingredient], emphasizing bioavailability and targeted release.
- Its narrow claims restrict the scope but create a solid barrier in the US market.
- The landscape includes broader formulation patents and method claims, with potential for carve-outs.
- Geographical coverage impacts global licensing and competitive strategies.
- The patent reinforces the therapeutic’s innovation, influencing investment and development planning.
FAQs
-
What are the main limitations of the claims in U.S. Patent 12,295,935?
The claims are limited to specific formulations, delivery methods, and treatment protocols, excluding claims on the active compound alone.
-
How does this patent compare to prior art?
It is more specific regarding delivery system and formulation, differentiating from earlier patents that covered broader compounds or formulation types.
-
Could competitors design around this patent?
Yes. Alternatives include developing different formulations, delivery mechanisms, or using different excipients not claimed in the patent.
-
What is the potential for patent infringement in other jurisdictions?
Since filings extend to Europe, Canada, and Japan, infringement risks exist; companies should review local patent laws and claims.
-
What is the strategic significance of this patent for pharmaceutical companies?
It offers exclusivity on specific formulations, preventing direct competition and supporting market positioning for the targeted therapy.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 12,295,935.
[2] Patent landscape reports and related filings.
[3] Prior art references and publication databases.
More… ↓
⤷ Start Trial
|
